Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Trusopt Articles

Prasco starts shipping generic dorzolamide; Hi-Tech gets appro for same

3 November 2008

US Quarterly Financial Results Round-Up

23 April 1998

Aggrastat Backed For Unstable Angina

14 April 1998

Strong Growth For US Drug Firms In 1997

28 January 1998

US 3rd Quarter Results Show Strong Growth

22 October 1997

Merck's Sales Up 19% Amid Fears For The Future

17 October 1997

Solid Growth For US Firms Despite Strong $

24 July 1997

Dutch Government Reimbursement Blacklist Rises To 35

9 December 1996

First Launch Of P&U's Xalatan For Glaucoma

30 September 1996

First Approval Of Allergan's Alphagan

16 September 1996

US Drug Majors See 2nd-Half Double-Digit Growth

29 July 1996

Trusopt Launched In France

11 March 1996

NCEs In 1995: A Good Range Of Novel Drugs

29 January 1996

Merck Sharp and Dohme: Trusopt lastest

9 October 1995

Merck pipline report

3 July 1995

Merck's Trusopt

19 June 1995

New Chemical Entities Round-Up For 1994

6 February 1995

Trusopt Approved In USA

2 January 1995

MERCK FILES NDAs FOR COZAAR WORLDWIDE

21 February 1994

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS